Investor Presentaiton

Revenue performance by Geography J Sequent Proven Ability In Life Sciences ALIVIRA All values in Mn QoQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q4 FY23 Q3 FY23 QoQ Gr% Q4 FY22 YoY Gr% FY23 FY22 YoY Gr% (In cc) (In cc) (In cc) Formulations 2,559 2,588 (1.1%) (6.3%) 2,493 2.6% 2.9% 10,009 9,686 3.3% 9.9% Europe 1,146 1,050 9.1% 4.1% 1,024 11.9% 7.0% 4,147 4,205 (1.4%) 1.7% Emerging Markets 1,201 1,252 (4.1%) India 213 286 (25.7%) APIs 941 1,072 Other Sales 10 25 Global Sales 3,511 Adjustment* - Ind AS 29 156 Reported Sales 3,685 69 (12.1%) NM (4.7%) (10.5%) 1,253 (4.1%) (25.7%) 217 (12.2%) 1,273 NM 70 (8.4%) 3,837 (0.8%) (2.0%) (2.0%) 1,055 (26.1%) (31.8%) 3,808 NM NM ☐☐ 102 (8.5%) (10.2%) 13,920 14,128 4,807 4,461 7.8% 15.9% 1,021 3.4% 3.4% 4,314 (11.7%) (15.4%) 128 NM (1.5%) NM 2.2% 289 3,667 3,753 (2.3%) (8.0%) 3,837 (4.4%) (9.9%) 14,209 14,128 0.6% 2.2% Following strong growth in Q3, Q4 revenue was lower by 8% cc vs. Q3 FY23. Despite multiple headwinds across geographies, in FY23, recorded a growth of 2.2% y-o-y in cc terms Formulations Business :- Europe clocked 7% yoy growth in Q4. FY23 was relatively flat with growth of 1.7% over FY22. Implemented strategic initiatives to streamline operations and optimize cost structures. Emerging Markets segment continues its growth trajectory despite a muted LATAM sales during Q4 FY 23. In FY23, the region delivered a robust 15.9% cc growth despite major headwinds in Turkey. API business: Top 10 customers continue to contribute ~58% of sales. Comprehensive margin and operations improvement program underway. New investment in capacity expansion and R&D capability - cc Constant Currency *Adjustment on account of hyperinflation in Turkey as per Ind AS 29 _ NM Not Material 5

View entire presentation